The pharmaceutical industry's focus on rare diseases has intensified, with 57% of all novel drugs approved in 2025 designated as orphan treatments. This is a continued increase from prior years, indicating a strategic shift towards smaller patient populations with high unmet needs, as exemplified by three different drugs for Hereditary Angioedema (HAE) being approved within ten weeks.

The key to treating rare diseases is not just CRISPR technology but a regulatory shift toward an "umbrella" or "platform" strategy. This allows multiple drugs for different mutations to be tested under a single trial, drastically lowering costs and making it feasible to develop treatments for tiny patient populations.

The development of agents targeting specific mutations like CALR and JAK2V617F marks a move away from the "one size fits all" JAK inhibitor approach. This enables a more personalized, molecularly-driven treatment strategy that was previously not possible for MPN patients.

The FIGHT-302 trial for FGFR2-rearranged cholangiocarcinoma closed early, like similar trials, because the standard of care evolved faster than patients could be recruited. This highlights a fundamental challenge in studying rare molecular subtypes, requiring alternative trial designs where thousands of patients must be screened to find a few eligible participants.

Treating 'non-clear cell' kidney cancer as a single entity is a major research limitation. Experts argue that distinct histologies like papillary and chromophobe are different diseases. Future progress requires dedicated, international trials for each subtype rather than grouping them due to rarity.

While CAR-T therapy is known in blood cancers, engineered T-cell receptor (TCR) therapies are finding their first major successes in solid tumors within the sarcoma community. Treatments targeting MAGE-A4 and NY-ESO-1 in specific sarcomas are demonstrating high efficacy and leading development in the field.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

The formal FDA classification of "BCG-unresponsive" bladder cancer created a standardized patient population, which spurred a rapid increase in clinical trials for new therapies. This regulatory clarity was a key inflection point for innovation in the field.

The key takeaways from the major ASCO oncology conference are a continued strong push for Antibody-Drug Conjugates (ADCs), the rise of translational AI, and a strategic shift towards pan-tumor approaches that can address a wide panel of cancers rather than focusing on a single indication.